Mesenchymal stem cell-derived extracellular vesicles and their use

What is AI technical title?
AI technical title is built by Patsnap AI team. It summarizes the technical point description of the patent document.
Extracellular vesicles from mesenchymal stem cells, enriched with specific microRNAs, address the limitations of current treatments by effectively inhibiting fibrosis-related proteins and collagen production, offering a promising therapy for pulmonary fibrosis.

JP2026524877APending Publication Date: 2026-07-24CORESTEM CO LTD

0 Cites 0 Cited by

Patent Information

Application Number: JP2025575965
Authority / Receiving Office: JP · JP
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2023-06-29
Filing Date: 2024-06-27
Publication Date: 2026-07-24

Application Information

Patent Timeline

29 Jun 2023

Priority

27 Jun 2024

Application

JP2025575965

24 Jul 2026

Publication

JP2026524877A

IPC: C12N5/10; C12N15/113; C12N5/071; C12N5/0775; A61K31/7105; A61K35/28; A61P11/00

CPC: C12N15/113; A61P11/00; A61K35/28; C12N2320/32; C12N2310/141; C12N5/0665; C12N2501/65; C12N2501/599

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

AI Tagging

Application Domain

Organic active ingredients Cell dissociation methods

Technology Topics

Fibrosis Thelial cell

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

AI Technical Summary

Technical Problem

Current treatments for idiopathic pulmonary fibrosis, such as pirfenidone and nintedanib, do not address the underlying cause and have tolerability issues and side effects, while mesenchymal stem cells face challenges with engraftment and survival variability, posing risks of cancer transformation.

Method used

Development of extracellular vesicles derived from mesenchymal stem cells, containing specific microRNAs like hsa-miR-148a-3p, hsa-miR-100-5p, hsa-miR-143-3p, and hsa-let-7a-5p, which inhibit fibrosis-related protein expression and collagen production.

Benefits of technology

The extracellular vesicles significantly reduce fibrosis-related proteins and collagen production, effectively preventing and treating pulmonary fibrosis in animal models.

✦ Generated by Eureka AI based on patent content.

Patent Text Reader

Abstract

This invention relates to extracellular vesicles derived from human mesenchymal stem cells and their use. The extracellular vesicles derived from mesenchymal stem cells according to the present invention inhibit the expression of fibrosis-related proteins, wound closure, and cell infiltration, which are increased in lung epithelial cells due to TGF-β1 treatment. In addition, microRNAs contained in large quantities in the extracellular vesicles inhibit the gene expression of fibrosis-related proteins in lung epithelial cells and lung fibroblasts. These extracellular vesicles significantly reduce the expression of fibrosis-related proteins, collagen production, and fibrotic areas in a mouse model of pulmonary fibrosis. Therefore, the extracellular vesicles according to the present invention can be used to prevent and treat pulmonary fibrosis.

Need to check novelty before this filing date? Find Prior Art